register

News & Trends - MedTech & Diagnostics

New partnership eliminates co-payment for robotic-assisted surgery

Health Industry Hub | December 12, 2022 |

MedTech News: Robot technology is increasingly used in cancer surgery such as radical prostatectomy and in the treatment of kidney and bladder cancer.

Not-for-profit health insurer HBF has reached an agreement with Ramsay Health Care that will see surgery become more affordable for eligible HBF members undergoing robotic-assisted procedures at Ramsay’s WA hospitals.

A recent survey of of 4,000 consumers revealed that private health insurance costs topped the list of concerns for Australians. It is therefore critical for private health insurers to show value for the these costs.

HBF’s Executive General Manager Insurance and Health Services, Dr Daniel Heredia, said the arrangement with Ramsay Health Care would alleviate the higher costs associated with robotic procedures, with the agreement removing the substantial co-payment previously paid by members undergoing robotic-assisted surgery.

“Affordability – out-of-pocket fees in particular – is one of the biggest pain points for our members,” he said.

“Procedures performed using a robotic surgical system have additional consumables that can be significantly more expensive than when the same surgery is performed using other surgical techniques.

“At a time when members are already distressed about their health, this is one less thing for them to worry about.”

Dr Heredia said as a not-for-profit insurer with no shareholders to pay, HBF had an ongoing commitment to driving better member outcomes, including ensuring out-of-pocket expenses were kept to a minimum.

“We take the responsibility of keeping our products affordable and accessible to our members very seriously,” he said.

“HBF is pleased to have reached this agreement with Ramsay Health Care that will deliver certainty, enhance the value of private health insurance and improve our members’ overall experience.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.